Filing Flows › PAVmed (PAVM) › Q1 2026 › vs Q1 2025
PAVmed (PAVM) Q1 2026 vs Q1 2025 (year over year)
PAVmed's revenue rose $14K (+175%) from $8K in Q1 2025 to $22K in Q1 2026.
PAVmed, Q1 2026: revenue $22K (+175% year over year), net loss $1.1M, operating cash flow −$2.6M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $22K | $8K | $14K | +175% |
| Other income, net | $7.0M | $24.1M | −$17.1M | -71% |
| Net loss | $1.1M | −$18.6M | $19.7M | — |
| Costs & expenses | $8.1M | $24.1M | −$16.0M | -67% |
| Operating costs | $8.1M | $5.5M | $2.6M | +48% |
| Cost of revenue | $97K | $36K | $61K | +169% |
| Research & development | $1.4M | $787K | $601K | +76% |
| Sales & marketing | $216K | $247K | −$31K | -13% |
| General & admin | $6.4M | $4.4M | $2.0M | +45% |
| Operating cash sources | $2.8M | $2.6M | $268K | +10% |
| Depreciation & amortization | $20K | $43K | −$23K | -53% |
| Share-based compensation | $182K | $930K | −$748K | -80% |
| Cash used in operations | $2.6M | $1.6M | $1.0M | +66% |
| Net loss absorbed | $1.1M | −$18.6M | $19.7M | — |
| Working capital & other | $1.8M | $21.2M | −$19.4M | -92% |
Questions
How much did PAVmed's revenue grow year over year in Q1 2026?
PAVmed's revenue rose $14K (+175%) from $8K in Q1 2025 to $22K in Q1 2026.